mechanism

Mini-Review

RNAi mechanisms and applications

Daniel H. Kim and John J. Rossi

BioTechniques 44:613-616 (25th Anniversary Issue, April 2008)

doi 10.2144/000112792

Within the past two decades we have become increasingly aware of the roles that RNAs play in regulation of gene expression. The RNA world was given a booster shot with the discovery of RNA interference (RNAi), a compendium of mechanisms involving small RNAs (less than 30 bases long) that regulate the expression of genes in a variety of eukaryotic organisms. Rapid progress in our understanding of RNAi-based mechanisms has led to applications of this powerful process in studies of gene function as well as in therapeutic applications for the treatment of disease. RNAi-based therapies involve two-dimensional drug designs using only iden-tification of good Watson-Crick base pairing between the RNAi guide strand and the target, thereby resulting in rapid design and testing of RNAi triggers. To date there are several clinical trials using RNAi, and we should expect the list of new applications to grow at a phenomenal rate. This article summarizes our current knowledge about the mechanisms and applications of RNAi.

Vol. 44 ? No. 5 ? 2008 http://wendang.chazidian.com ? BioTechniques 25th Anniversary ? 613

Mini-Review

transcripts (reviewed in References 17 and 18). The latter approach is primarily based on nuclear synthesis of short-hairpin RNAs (shRNAs), which are transported to the cytoplasm via the miRNA export pathway and are processed into siRNAs by Dicer. While direct use of synthetic siRNA effectors is simple and usually results in potent gene silencing, the effect is transient. DNA-based RNAi drugs, on the other hand, have the potential of being stably introduced when used in a gene therapy setting, allowing, in principle, a single treatment of viral vector-delivered shRNA genes.The first clinical applications of RNAi have been directed at the treatment of age-related macular degeneration (AMD), which causes blindness or limited vision in millions of adults annually (19,20). Therapies based on RNAi are also currently being developed for viral infection, including human immunode-ficiency virus (HIV), hepatitis B and C viruses (HBV and HCV), and respiratory syncytial virus (RSV) (21). Strategies for the treatment of neurodegenerative diseases and cancers are also well under way.Although successful in vivo studies have shown the potential effectiveness of RNAi-based therapies, other studies have illustrated specific approaches to avoid when adopting an endogenous cellular mechanism for therapeutic benefit. Unwanted side effects have included activation of Toll-like receptors (TLRs) and type 1 interferon responses, and competition with the endogenous RNAi pathway components (22). These findings indicate that although RNAi is potentially a revolutionary mechanism for treatment of disease, due caution is necessary when interpreting results from RNAi-mediated target knockdowns.The challenge of cell- or tissue-specific delivery of siRNAs is also crucial when investigating the utility of RNAi-based therapies for a given disease; various strategies for nonviral and viral delivery of RNAi triggers have shown to be effective in their respective disease models. The relative advantages and disadvantages of using synthetic siRNAs versus expressed shRNAs must also be taken into consid-eration when designing RNAi-based therapies for a particular disease.Chemically synthesized siRNAs are commonly screened for effective Figure 1.Cellular pathways of gene silencing by RNA interference. RNAi is multifaceted, and there are various pathways in which small double-stranded RNA (dsRNAs) regulate gene expression.

Crick base pairing to the 3′ untranslated regions of targeted mRNAs. Alternatively, perfectly duplexed small interfering RNAs (siRNAs) can be produced intracellularly or supplied exogenously to cells. The guide strand is incorporated into the RNA-induced silencing complex (RISC), where it guides sequence-specific degradation of the target transcript, irrespective of where the base pairing occurs. The miRNA and siRNA pathways are interchangeable, and the important determinants are the posi-tions within the message and the extent of base pairing with the targeted transcripts. siRNAs can also trigger transcriptional gene silencing via interactions with chromatin, wherein they guide histone and DNA methylation leading to inactive chromatin. knockdown of a specific target gene. To increase siRNA stability, chemical modifications are introduced, such as 2′-O-methylpurines or 2′-fluoropyrimidines (23). When initially designing a siRNA molecule, computational algorithms are routinely used that incorporate various parameters, including siRNA duplex end stabilities for proper strand selection and mRNA secondary structures for target site accessibility. To improve the potency of an RNAi response, siRNA duplexes can also be designed to mimic substrates for Dicer processing (24). Longer siRNAs (e.g., 27-mers) are incorporated into the Dicer loading step of the RNAi pathway and may facilitate the activation of RISC. 27-mers are designed asymmetrically to exhibit a 2 nt 3′ ov overhang on one end and a blunt region on the other (25), which guides Dicer processing and biogenesis of the proper guide strand, since the PAZ domain of Dicer recognizes the overhang end. Furthermore, because of the efficiency of 27-mers in mediating gene silencing, a lower concentration of siRNAs can mediate a potent RNAi response.From the perspective of therapeutic applications of RNAi, the most important concern is delivery of the siRNAs to the appropriate tissue. Numerous recent publications have shown that siRNAs can be systemically delivered to various tissues with resultant knockdown of target RNAs. Intravenous injection of siRNAs for systemic delivery is accomplished through conjugation of siRNA molecules to a cholesterol group or the packaging of siRNAs into liposomal particles. Systemic delivery using these approaches is effective

Vol. 44 ? No. 5 ? 2008614 ? BioTechniques 25th Anniversary ? http://wendang.chazidian.com

Mini-Review

for delivery to the liver and jejunum, but may not be appropriate for delivery to other organs. In a proof-of-concept study, siRNAs targeting apolipoprotein B (APOB) were used to modify cholesterol metabolism. The 3′siRNA passenger strand was chemically linked to a cholesterol group, and these conjugated siRNAs effectively knocked down gene expression by >50% in the liver and 70% in the jejunum (26).

Another approach for systemic delivery involves the use of specialized lipid bilayers called stable nucleic acid-lipid particles (SNALPs), which incor-porate chemically modified siRNAs (27). Cationic and neutral lipids comprise the bilayer, along with an outer hydrophilic coating of polyethylene glycol (PEG). In one study, monkeys were adminis-tered a single dose of siRNA-containing SNALPs, which lowered cholesterol levels for 11 days or longer, with <10% of

APOB expression remaining in the liver of this nonhuman primate model (28).

????hhshsasasa-lelet-7let-77ahsa-miR-107???hsahsaa--leleett-t-7-7-7bhsa-miR-122a????hhshsasa-lesa-l-lett-7t--chsa-miR-126????hhsasa-lelet-7let7dhsa-miR-127hshhsasaa-lelett-77ehshsahsa-miR-128asa????hhshsasa-lesletlt-77f??hhshsasaa-mimiRmiR-1R--1-1228b8b?????hsahshsaa-lelet-7let-77g??hshshsasa-m-mimiR-miR-1R-1-12299????hsahshs-lesalelett-7t--7i-7??hhsasa-misa-mi-mmRR-R-1--1130300aa

????hsahshsa-msa-mimimiRR-1--11??hshsahsaa--mi-mmimiRR-1R--1330b3000bb

???hsahsaa-mi-mmimiR-1R--110000??hsah-mhs-mimimiRR-1R--1-13322????hsahshssaa--mmimiR-1R-1R--10303?h??hsaa-mi-mmimiR-1R-R-13-1344????hhsasaa--m-mimiRmiR-1-105-1??hhshsasa-misa-miR-1-mR--11335a355a???hsahsahsa-m-mi-mimiRR-1-1-100aa??hhshsasasa-mi-mi-mmR-R-1R-1-1335b355b5b?hhsasaa-m-mimiR-R-1R-1-10b0bhshsahsasa-mi-R-mR-13R-1366???hhsahssasa-mi-m-mmiiRR-1--1133a3333a??hhssasa-mimiRmiR-R-1-13377????hhsahssasa-m-mi-mimiRR-1-1133333b3b3b??hhshsasa-sa-mmiRR-1R--14400???hhshsasasa-mmimiRR-R-1-1-14242-42-2-3p3p??hhsasa-misa-m-miRR-1-1-4141????hsahsahssa--mmiRmiR-1R--115a5a??hhssasa-mi-mmiRmiR-R-1-1-1434????hhshsasasa--mmiR-1miR-15R-5bb??hshssaaRR-1-145-145???hshsahsasa--mi-mmimiR-1R6R-??hs-146-14646a6aa????hsahsaa--m-mimiiRR-18R-182*822*2*?46b4646b6b????hhsasaa-m-mmiiRR-184R-184hsahshsasa-misa-mmiRR-R-1-118a8ahsa-miR-10?????hhsahssa-misa-mmiiRR-R-1-18a8a*8a**hsa-miR-151

????hhsahssasa-m-mimiRmiR-R-1-1188bbhsa-miR-152

???hhssasa-m-miRR-R-1-199a-19aa??hsa-miR-153???hhsasaa-miRR-1R--1199b999bbhsa-miR-154???hsahshsa-misa-mmiR-2miR-220a0ahsa-miR-154*????hsahsahsa-mmimiR-2R200bbhsa-miR-155????hshsahsasa-mi-m-mimiRR-2-221144??hsa-miR-182????hhssasa-mimimiR-2R-R-223a3a??hsa-miR-183No noticeable toxicities were observed,

suggesting the potential utility of this method in systemic delivery.

For the in vivo efficacy of siRNA molecules, the dosage of delivered siRNAs is a practical consideration, and selective delivery of siRNAs to specific tissues would potentially lower the effective dosage required. Targeting cell surface receptors is an advantageous approach, as it would lower the siRNA dosage and potentially avoid off-target effects from siRNA delivery to irrelevant tissues. The coupling of siRNAs to aptamers or antibody fragments, or the use of nanopar-ticles coated with receptor-specific ligands, allows for the specific delivery of siRNA payloads to targeted cells and tissues. For targeting of HIV-infected cells, siRNAs were coupled to heavy chain antibody fragments (Fabs) that recognize the HIV envelope glycoprotein gp120. Positively charged protamine was conjugated to Fab molecules, and the negatively charged siRNAs interacted electrostatically with the protamine to form a Fab-siRNA complex. This antibody-based approach demonstrated >70% knockdown of p24 group-specific antigen protein (Gag) when targeting cultured T lymphocytes infected with HIV-1 (29). A different targeting approach took advantage of a peptide from rabies virus, which specifically binds to the acetylcholine receptor. When this peptide was conjugated to a polyarginine peptide that binds siRNAs, delivery of siRNAs to the central nervous system was accomplished, resulting in inhibition of a fatal encephalitis viral infection (30).

Aptamers, which are structured RNA ligands, can be designed to bind specifi-cally to cell surface receptors and be covalently linked to siRNAs for specific in vivo delivery. One method used aptamers that bind to the prostate-specific membrane antigen (PSMA) expressed on the surface of prostate cancer cells. When conjugated to siRNAs, these aptamer-siRNA hybrids effectively reduced tumor growth in mice (31). A similar approach using both bioti-

Receive your custom designed array in two weeks. Only pay for the miRNAs you need with FlexmiR Select.

Focus on miRNAs that are most relevant to your study.

FlexmiR Select miRNA arrays are the perfect and biomarker validation.

Multiplex 2-50 miRNA targets of interest in a single well.

xMAP®

provide accurate results in 4-5 hours without sample manipulation or bias. Quantitative data can be attained with standard curves.

Custom build your FlexmiR Select array online with Luminex’s Custom Array Builder (CAB).

Build your own customized miRNA array with our online Custom Array Builder (CAB) at http://wendang.chazidian.com/CAB

Contact us at 512.219.8020 (United States) or +31.162.408333 (Europe)

Mini-Review

nylated siRNAs and aptamers bound to the Diseases and the NIH Heart Lung biotin-binding protein streptavidin made and Blood Institute to J.J.R. D.H.K. is use of 27-mer siRNAs to potently induce supported by a City of Hope pre-doctoral gene silencing (32).

fellowship.

Coating nanoparticles with cell type–specific ligands is another powerful approach to systemically deliver RNAi-COMPETING INTERESTS inducing molecules. In an important STATEMENT

proof-of-concept study, Ewing sarcoma tumors were targeted in vivo with trans-The authors declare no competing ferrin ligand-coated nanoparticles (33). interests.

These nanoparticles were constructed using cyclodextrin-containing polyca-tions (CDPs) specifically designed to REFERENCES

incorporate negatively charged siRNA molecules. For added stability and to 1. Almeida,R.andR.C.Allshire. 2005. RNA silencing prevent aggregation, PEG polymers and genome regulation. Trends Cell Biol. 15:251-258.2. Zhang,H.,F.A.Kolb,L.Jaskiewicz,E.Westhof, andwere attached to the outer surface using W.Filipowicz. 2004. Single processing center models terminal adamantane groups. Transferrin for human Dicer and bacterial RNase III. Cell 118:57-68.ligands were then covalently linked to the 3. Lee,Y.,I.Hur,S.Y.Park,Y.K.Kim,M.R.Suh, andadamantane-PEG chains, and the nanopar-V.N.Kim. 2006. The role of PACT in the RNA silenc-ticle design allowed for self-assembly into ing pathway. EMBO J. 25:522-532.4. Meister,G.,M.Landthaler,A.Patkaniowska,uniform, ?50 nanometer-sized nanopar-Y.Dorsett,G.Teng, andT.Tuschl. 2004. Human ticles. The nanoparticle-incorporated Argonaute2 mediates RNA cleavage targeted by miR-siRNAs targeted the Ews-Fli1 (EwingNAs and siRNAs. Mol. Cell 15:185-197.5. Liu,J.,M.A.Carmell,F.V.Rivas,C.G.Marsden,sarcoma breakpoint region 1-flightless 1 J.M.Thomson,J.J.Song,S.M.Hammond,L.homolog) gene fusion product and were Joshua-Tor, et al. 2004. Argonaute2 is the catalytic en-gine of mammalian RNAi. Science. 305:1437-41shown to inhibit tumor l formation in mice 6. Tang,G. 2005. siRNA and miRNA: an insight into (33).

RISCs. Trends Biochem. Sci. 30:106-114.7. Schwarz,D.S.,G.Hutvagner,T.Du,Z.Xu,N.Aronin, andP.D.Zamore. 2003. Asymmetry in the Concluding Remarks

assembly of the RNAi enzyme complex. Cell 115:199-208.8. Khvorova,A.,A.Reynolds, andS.D.Jayasena. 2003. In summary, the progression from the Functional siRNAs and miRNAs exhibit strand bias. initial discovery of RNAi to its clinical Cell 115:209-216.applications has been astounding. 9. Bartel,D.P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297.Understanding the fundamental biology 10. Bartel,D.P.andC.Z.Chen. 2004. Micromanagers of of RNAi has led to its widespread applica-gene expression: the potentially widespread influence of metazoan microRNAs. Nat. Rev. Genet. 5:396-400.tions in basic research and subsequently in 11. Bagga,S.,J.Bracht,S.Hunter,K.Massirer,J.Holtz,applications for the treatment of disease. R.Eachus, andA.E.Pasquinelli. 2005. Regulation by Within the next few years we should let-7 and lin-4 miRNAs results in target mRNA degra-dation. Cell 122:553-563.expect to unravel more RNAi-mediated 12. Leuschner,P.J.,S.L.Ameres,S.Kueng, andJ.regulation of gene expression, and will Martinez. 2006. Cleavage of the siRNA passenger also see RNAi-based drugs approved for strand during RISC assembly in human cells. EMBO Rep. 7:http://wendang.chazidian.come in the treatment of disease. In addition, 13. Gregory,R.I.,T.P.Chendrimada,N.Cooch, andR.RNAi has proven to be a powerful tool Shiekhattar. 2005. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell for the study of gene function and has 123:631-640.opened new areas of basic investigation. 14. Matranga,C.,Y.Tomari,C.Shin,D.P.Bartel, andIn the near future we should see continued P.D.Zamore. 2005. Passenger-strand cleavage facili-tates assembly of siRNA into Ago2-containing RNAi development in our understanding and enzyme complexes. Cell 123:607-620.application of this remarkable cellular 15. Lee,Y.,C.Ahn,J.Han,H.Choi,J.Kim,J.Yim,mechanism for posttranscriptional J.Lee,P.Provost,et al. 2003. The nuclear RNase III Drosha initiates microRNA processing. Nature 425:415-regulation of gene expression.

419.16. Han,J.,Y.Lee,K.H.Yeom,Y.K.Kim,H.Jin, andV.N.Kim. 2004. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 18:3016-ACKNOWLEDGMENTS

3027.17. Hannon,G.J.andJ.J.Rossi. 2004. Unlocking the This work was supported by the potential of the human genome with RNA interference. Nature 431:371-378.National Institutes of Health National 18. Scherer,L.J.andJ.J.Rossi. 2003. Approaches for Institute of Allergy and Infectious

the sequence-specific knockdown of mRNA. Nat. Biotechnol. 21:1457-1465.

616 ? BioTechniques 25th Anniversary ? http://wendang.chazidian.com 19. Fattal,E.andA.Bochot. 2006. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv. Drug Deliv. Rev. 58:1203-1223.20. Tolentino,M. 2006. Interference RNA technology in the treatment of CNV. Ophthalmol. Clin. North Am. 19:393-399, vi-vii.21. Leonard,J.N.andD.V.Schaffer. 2006. Antiviral RNAi therapy: emerging approaches for hitting a moving tar-get. Gene Ther. 13:532-540.22. Svoboda,P. 2007. Off-targeting and other non-specific effects of RNAi experiments in mammalian cells. Curr. Opin. Mol. Ther. 9:248-257.23. Czauderna,F.,M.Fechtner,S.Dames,H.Aygun,A.Klippel,G.J.Pronk,K.Giese, andJ.Kaufmann.2003. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31:2705-2716.24. Kim,D.H.,M.A.Behlke,S.D.Rose,M.S.Chang,S.Choi, andJ.J.Rossi. 2005. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23:222-226.25. Amarzguioui,M.,P.Lundberg,E.Cantin,J.Hagstrom,M.A.Behlke, andJ.J.Rossi. 2006. Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat. Protocols 1:508-517.26. Soutschek,J.,A.Akinc,B.Bramlage,K.Charisse,R.Constien,M.Donoghue,S.Elbashir,A.Geick,et al. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173-178.27. Morrissey,D.V.,J.A.Lockridge,L.Shaw,K.Blanchard,K.Jensen,W.Breen,K.Hartsough,L.Machemer,et al. 2005. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23:1002-1007.28. Zimmermann,T.S.,A.C.Lee,A.Akinc,B.Bramlage,D.Bumcrot,M.N.Fedoruk,J.Harborth,J.A.Heyes,et al. 2006. RNAi-mediated gene silencing in non-hu-man primates. Nature 441:111-114.29. Song,E.,P.Zhu,S.K.Lee,D.Chowdhury,S.Kussman,D.M.Dykxhoorn,Y.Feng,D.Palliser,et al. 2005. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23:709-717.30. Kumar,P.,H.Wu,J.L.McBride,K.E.Jung,M.H.Kim,B.L.Davidson,S.K.Lee,P.Shankar, et al.2007. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:39-43.31. McNamara,J.O.,II,E.R.Andrechek,Y.Wang,K.D.Viles,R.E.Rempel,E.Gilboa,B.A.Sullenger, andP.H.Giangrande. 2006. Cell type-specific de-livery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24:1005-1015.32. Chu,T.C.,K.Y.Twu,A.D.Ellington, andM.Levy.2006. Aptamer mediated siRNA delivery. Nucleic Acids Res. 34:e73.33. Hu-Lieskovan,S.,J.D.Heidel,D.W.Bartlett,M.E.Davis, andT.J.Triche. 2005. Sequence-specific knock-down of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a mu-rine model of metastatic Ewing’s sarcoma. Cancer Res. 65:8984-8992.

Address correspondence to John J. Rossi, Division of Molecular Biology, Beckman Research Institute of the City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA. e-mail: jrossi@http://wendang.chazidian.com

To purchase reprints of this article, contact: Reprints@http://wendang.chazidian.com

Vol. 44 ? No. 5 ? 2008